1. Home
  2. HNVR vs RCEL Comparison

HNVR vs RCEL Comparison

Compare HNVR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanover Bancorp Inc.

HNVR

Hanover Bancorp Inc.

N/A

Current Price

$21.51

Market Cap

147.6M

Sector

Finance

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.68

Market Cap

132.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNVR
RCEL
Founded
2008
N/A
Country
United States
United States
Employees
N/A
226
Industry
Commercial Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.6M
132.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
HNVR
RCEL
Price
$21.51
$3.68
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$24.50
$7.88
AVG Volume (30 Days)
4.2K
171.0K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.88%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
N/A
N/A
Revenue This Year
$35.49
$17.17
Revenue Next Year
$8.61
$49.82
P/E Ratio
$21.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.31
$3.22
52 Week High
$24.36
$10.28

Technical Indicators

Market Signals
Indicator
HNVR
RCEL
Relative Strength Index (RSI) 45.59 34.19
Support Level $20.44 $3.33
Resistance Level $22.41 $3.71
Average True Range (ATR) 0.51 0.28
MACD 0.12 -0.11
Stochastic Oscillator 53.23 6.56

Price Performance

Historical Comparison
HNVR
RCEL

About HNVR Hanover Bancorp Inc.

Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: